張 偉 ： 男，1957年10月生，藥理學(xué)教授，藥理藥劑內(nèi)科學(xué)研究生導(dǎo)師。1990年6月研究生畢業(yè)于安徽醫(yī)科大學(xué)心血管藥理專(zhuān)業(yè)，獲醫(yī)學(xué)碩士學(xué)位，無(wú)黨派人士。 現(xiàn)任南通大學(xué)醫(yī)學(xué)院藥理學(xué)系主任；南通大學(xué)醫(yī)藥研究所所長(zhǎng)；南通大學(xué)藥學(xué)（省重點(diǎn)一級(jí)學(xué)科培育點(diǎn)）學(xué)科帶頭人；南通大學(xué)省優(yōu)勢(shì)學(xué)科《基礎(chǔ)醫(yī)學(xué)》學(xué)科（群） 學(xué)術(shù)帶頭人（PI）。社會(huì)兼職：南通偉康醫(yī)藥研究院院長(zhǎng)（獨(dú)立法人）；南通市生物醫(yī)藥重點(diǎn)實(shí)驗(yàn)室常務(wù)副主任。學(xué)術(shù)團(tuán)體任職：中國(guó)藥理學(xué)會(huì)理事；江蘇省藥理 學(xué)會(huì)副理事長(zhǎng)；江蘇省藥理教學(xué)委員會(huì)副主任委員；江蘇省新藥臨床前研究專(zhuān)業(yè)委員會(huì)副秘書(shū)長(zhǎng)；南通市藥學(xué)會(huì)藥劑藥理專(zhuān)業(yè)委員會(huì)主任委員。從事新藥研究與開(kāi)發(fā) 三十多年，先后主持或與企業(yè)合作承擔(dān)各類(lèi)中西醫(yī)藥研發(fā)項(xiàng)目30多項(xiàng)，絕大多數(shù)成果轉(zhuǎn)化為生產(chǎn)力，其中有知名品牌“蓋天力”、“富硒康”、“安奇”等，有 “九五”科技攻關(guān)項(xiàng)目抗高血壓新藥Moxonidine、抗炎新藥Tenoxicam等，技術(shù)貿(mào)易（技術(shù)開(kāi)發(fā)、技術(shù)服務(wù)、技術(shù)轉(zhuǎn)讓?zhuān)┻_(dá)1000多萬(wàn)，近年 來(lái)主持國(guó)家、省、市廳級(jí)研究課題9項(xiàng)，獲市廳級(jí)科技進(jìn)步二等獎(jiǎng)3項(xiàng)（名第一）, 作為通訊作者（或第一作者）在國(guó)內(nèi)外核心與權(quán)威期刊發(fā)表專(zhuān)業(yè)學(xué)術(shù)論文40多篇，擁有國(guó)家授權(quán)發(fā)明專(zhuān)利5項(xiàng)。

通訊作者（或第一作者）代表作：

15．Stat3 pathway correlates with the roles of leptin in mouse liver fibrosis and sterol regulatory element binding protein-1c expression of rat hepatic stellate cells Int J Biochem Cell Biol．． 2013 Mar;45(3):736-44．

14．Two novel hydroperoxylated products of 20(S)-protopanaxadiol by Mucor racemosus and their cytotoxic activities against human prostate cancer cells Biotechnol Lett． 2013 Mar;35(3):439-43．

13．Proteomic analysis for anti-atherosclerotic effect of tetrahydroxystilbene glucoside in rats． Biomed Pharmacother． 2012 Nov 15．doi:pii: S0753-3322PMID: 23178522

12．Microbial transformation of 20(S)-protopanaxadiol by Absidia corymbifera． Cytotoxic activity of the metabolites against human prostate cancer cells．

Fitoterapia． 2013 Jan;84:6-10

11．The effect of 2, 3, 4', 5-tetrahydroxystilbene-2-0-?-D glucoside on neointima formation in a rat artery balloon injury model and its possible mechanisms

Eur J Pharmacol． 2013 Jan ;698(1-3):370-8

10．MiR-17-3p Inhibits Angiogenesis by Downregulating Flk-1 in the Cell Growth Signal Pathway． J Vasc Res． 2012 Dec;50(2):157-166．

9．Electrical Field Stimulation Induces Cardiac Fibroblast Proliferation through Calcineurin-NFAT Pathway．

Can J Physiol Pharmacol． 2012 Dec;90(12):1611-22．

8．SKF83959, an Agonist of the Phosphatidylinositol-Linked D1-Like Receptors, Promotes ERK1/2Activation and Cell Migration in Cultured Rat Astrocytes．

PLoS One． 2012 Nov;7(11):e49954．

7．2,3,4’,5-Tetrahydroxystilbene-2-0-beta-D-glucoside inhibits proliferation of

Vascular smooth muscle cells：involvement of NO/cGMP/PKG pathway．

Phytotherapy Research． 2012 Jul;26(7):1068-74

6．2,3,4',5-Tetrahydroxystilbene-2-O-beta-D-glucoside Inhibits angiotensin II-induced

cardiac fibroblast proliferation through suppression of reactive oxygen species-ERK1/2

pathway． Clin Exp Pharmacol Physiol． 2012 May;39(5):429-37．

5．2,3,4',5-Tetrahydroxystilbene-2-0-beta-D-glucoside inhibits platelet-derived growth

factor-induced proliferation of vascular smooth muscle cells by regulating cell cycle．

Clin Exp Pharmacol Physiol． 2011May;38(5):307–313

4．Ca2+?calmodulin-dependent protein kinase IIδ orchestrates G-protein-coupled

receptor and electric ?eld stimulation-induced cardiomyocyte hypertrophy

Clin Exp Pharmacol Physiol 2010 Aug;37(8):795–802

3．Inhibition of Calcium-Calmodulin-Dependent Kinase II Suppress Cardiac

Fibroblast Proliferation and Extracellular Matrix Secretion ．

J Cardiovasc Pharmacol 2010 Jan;55(1):96-105

2．Effects of 2,3,4’,5-Tetrahydroxystilbene-2-0-β-D-glucoside on vascular endothelial

dysfunction in atherogenic-diet rats Planta Medicinal 2009 Sep;75:1209-1214

1．2,3,4’,5-TETRAHYDROXYSTILBENE-2-O-β-D-GLUCOSIDE SUPPRESSES MATRIX METALLOPROTEINASE EXPRESSION AND INFLAMMATION IN ATHEROSCLEROTIC

RATS． Clin Exp Pharmacol Physiol 2008 Mar;35(3):310-6．

*如果發(fā)現(xiàn)導(dǎo)師信息存在錯(cuò)誤或者偏差，歡迎隨時(shí)與我們聯(lián)系，以便進(jìn)行更新完善。 聯(lián)系方式>>